Search For

Divergent transcriptional programs and constrained metabolic states reveal selective metabolic dependencies in chemoresistant luminal breast cancer

TROP2-targeting antibody–drug conjugates in breast cancer and ovarian carcinoma: therapeutic advances and resistance mechanisms

Integrating genomic mutations and tumor-infiltrating lymphocytes improves prediction of response to trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer

Decoding breast cancer treatment resistance through genetic, epigenetic, and immune-regulatory mechanisms: from molecular insights to translational perspectives

Antibody-drug conjugates in breast cancer: current resistance mechanisms and future combination strategies

FGFR1 overexpression promotes resistance to PI3K inhibitor alpelisib in luminal breast cancer cells through receptor tyrosine kinase signaling-mediated activation of the estrogen receptor

Antibody-drug conjugates in breast cancer treatment: resistance mechanisms and the role of therapeutic sequencing

Optimizing therapeutic approaches for HR+/HER2- advanced breast cancer: clinical perspectives on biomarkers and treatment strategies post-CDK4/6 inhibitor progression

Breast cancer cell resistance to hormonal and targeted therapeutics is correlated with the inactivation of the NR6A1 axis

Current applications of tumor local ablation (TLA) combined with immune checkpoint inhibitors in breast cancer treatment

The role of circRNAs and miRNAs in drug resistance and targeted therapy responses in breast cancer

Mechanisms of action and resistance to anti-HER2 antibody-drug conjugates in breast cancer